Can-Fite Biopharma (CANF) EBITDA (2010 - 2025)
Can-Fite Biopharma (CANF) EBITDA from Sep 30, 2010 to Jun 30, 2025. The TTM Can-Fite Biopharma (CANF) EBITDA is -$8.90M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Can-Fite Biopharma (CANF) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +14.25% |
| 3 Years TTM | -9.41% |
| 5 Years TTM | -10.47% |
| 10 Years TTM | +6.30% |
| All Time TTM | +5.00% |
Annual EBITDA change of Can-Fite Biopharma (CANF)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$10M | +23.15% |
| 2024 | -$8.12M | -0.73% |
| 2023 | -$8.18M | -18.85% |
| 2022 | -$10M | -21.43% |
| 2021 | -$13M | -9.20% |
| 2020 | -$14M | +17.85% |
| 2019 | -$12M | +95.60% |
| 2018 | -$6.13M | -14.50% |
| 2017 | -$7.17M | -17.40% |
| 2016 | -$8.68M | +35.63% |
| 2015 | -$6.40M | -10.11% |
| 2014 | -$7.12M | -20.98% |
| 2013 | -$9.01M | +50.67% |
| 2012 | -$5.98M | -18.42% |
| 2011 | -$7.33M | +107.65% |
| 2010 | -$3.53M | N/A |
Comparison Can-Fite Biopharma (CANF) five years EBITDA CAGR with competitors
Can-Fite Biopharma (CANF) five years EBITDA CAGR is -10.46%.